[go: up one dir, main page]

WO2003059394A3 - Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases - Google Patents

Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases Download PDF

Info

Publication number
WO2003059394A3
WO2003059394A3 PCT/FR2003/000074 FR0300074W WO03059394A3 WO 2003059394 A3 WO2003059394 A3 WO 2003059394A3 FR 0300074 W FR0300074 W FR 0300074W WO 03059394 A3 WO03059394 A3 WO 03059394A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
central nervous
brain barrier
blood brain
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/000074
Other languages
French (fr)
Other versions
WO2003059394A2 (en
WO2003059394A1 (en
Inventor
Pierre Vidal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Priority to AU2003222326A priority Critical patent/AU2003222326A1/en
Publication of WO2003059394A2 publication Critical patent/WO2003059394A2/en
Publication of WO2003059394A1 publication Critical patent/WO2003059394A1/en
Publication of WO2003059394A3 publication Critical patent/WO2003059394A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns a compound consisting of at least an oligonucleotide bound to at least a vector peptide capable of transporting it through the blood brain barrier (BBB). The invention also concerns the preparation of said compounds and pharmaceutical compositions containing same useful for preventing and/or treating diseases of the central nervous system.
PCT/FR2003/000074 2002-01-10 2003-01-10 Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases Ceased WO2003059394A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003222326A AU2003222326A1 (en) 2002-01-10 2003-01-10 Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200259A FR2834465A1 (en) 2002-01-10 2002-01-10 COMPOSITIONS FOR THE VECTORIZATION OF OLIGONUCLEOTIDES THROUGH THE HEMATOENCEPHALIC BARRIER AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
FR02/00259 2002-01-10

Publications (3)

Publication Number Publication Date
WO2003059394A2 WO2003059394A2 (en) 2003-07-24
WO2003059394A1 WO2003059394A1 (en) 2003-07-24
WO2003059394A3 true WO2003059394A3 (en) 2004-03-11

Family

ID=8871225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000074 Ceased WO2003059394A1 (en) 2002-01-10 2003-01-10 Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases

Country Status (3)

Country Link
AU (1) AU2003222326A1 (en)
FR (1) FR2834465A1 (en)
WO (1) WO2003059394A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968662B1 (en) 2010-12-10 2013-11-22 Roussy Inst Gustave NOVEL PRE-ACTIVE OXAZAPHOSPHORINE DERIVATIVES, USE AND METHOD OF PREPARATION
KR20190058477A (en) 2016-08-17 2019-05-29 솔스티스 바이올로직스, 리미티드 Polynucleotide construct
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. Chiral phosphoramidite auxiliaries and methods of their use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1998040502A1 (en) * 1997-03-14 1998-09-17 Life Technologies, Inc. Peptide-enhanced transfections
WO2000012114A1 (en) * 1998-09-01 2000-03-09 The Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
WO2002053583A2 (en) * 2001-01-03 2002-07-11 Synt:Em Amphipathic peptides and their use for transferring substances of interest into cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1998040502A1 (en) * 1997-03-14 1998-09-17 Life Technologies, Inc. Peptide-enhanced transfections
WO2000012114A1 (en) * 1998-09-01 2000-03-09 The Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
WO2002053583A2 (en) * 2001-01-03 2002-07-11 Synt:Em Amphipathic peptides and their use for transferring substances of interest into cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G DRIN & J TEMSAMANI: "Translocation of protegrin I through phospholipid membranes: role of peptide folding", BIOCHIMICA ET BIOPHYSICA ACTA., vol. 1559, no. 2, 2002 - 15 February 2002 (2002-02-15), AMSTERDAM, NL, pages 160 - 170, XP004341289, ISSN: 0006-3002 *
K MATSUZAKI ET AL.: "Membrane permeabilization of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog", BIOCHEMISTRY., vol. 36, no. 32, 1997, AMERICAN CHEMICAL SOCIETY. EASTON, PA., US, pages 9799 - 9806, XP002219531, ISSN: 0006-2960 *
L ZHANG ET AL.: "Interaction of cationic antimicrobial peptides with model membranes", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 276, no. 38, 21 September 2001 (2001-09-21), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US, pages 35714 - 35722, XP002219532, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
FR2834465A1 (en) 2003-07-11
AU2003222326A1 (en) 2003-07-30
WO2003059394A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
IL170120A (en) 1,2,4-triazine compounds, their use for preparation of medicaments for treating or preventing hiv, pharmaceutical compositions comprising the same and processes for their preparation
CA2427227A1 (en) Lactam compound
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004105700A3 (en) Compounds, methods and pharmaceutical compositions for inhibiting parp
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2001001748A3 (en) Peptide compounds that bind her2
WO2003070755A3 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
IL173348A (en) Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments
WO2002102793A3 (en) Quinazolinediones as antibacterial agents
ATE235244T1 (en) COMPOSITION FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL AND PATHOPSYCHOLOGICAL DISEASES
WO2002030405A3 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2003026700A3 (en) Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases
WO2004087652A3 (en) Imidazotriazine compounds
WO2005074989A3 (en) Combination of a dna topoisomerase inhibitor and an iap inhibitor
WO2005007083A3 (en) Chemical compounds
WO2003059394A3 (en) Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases
TW200716618A (en) Chemical compounds
WO2003024996A3 (en) Antibacterial macrocycles
HUP0302535A3 (en) Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
WO2001057069A3 (en) Targeting peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP